TNS Healthcare merges into KantarHealth

WPP formally launched KantarHealth, an amalgam of four companies that bundles global research with consulting capabilities.

The announcement follows WPP's acquisition of TNS in October 2008, and combines TNS Healthcare with Consumer Health Sciences, MattsonJack and Ziment. KantarHealth is led by co-CEOs Lynnette Cooke, formerly CEO at Ziment, and Elaine Riddell, previously the CEO at TNS Healthcare. Richard Martin, formerly COO at MattsonJack, is COO at KantarHealth.

According to Ilene Siegalovsky, SVP, global strategic marketing, the legacy companies' names will be phased out and will operate exclusively under the KantarHealth banner. With US headquarters in New York City, Siegalovsky said the company will be “managed globally,” with over 40 offices spread across the Americas, Europe, Asia-Pacific, the Middle East and Africa.

Siegalovsky said the company works with “literally every pharmaceutical and biotech company” in some capacity, including all of the top 10 pharmas. Mixing a consulting practice with research enables KantarHealth to provide practical business advice on top of raw information, said Siegalovsky, citing complaints about research groups in the past. “They provide great information, but it's not always particularly applicable. We organize around the consultancy…to focus on a specific aspect of a company's business,” she said.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.